www.aasraw.com
Lenvatinib
Lenvatinib Clinical Results(FDA Approval) The FDA approval of Lenvatinib was based on a multicenter, randomized, double-blind, placebo-controlled trial in 392 subjects with locally recurrent or metastatic radioactive iodine-refractory differentiated thyroid cancer and radiographic evidence of disease progression within 12 months prior to randomization, confirmed by independent radiologic review. The subjects received Lenvatinib 24 mg once daily (n=261) or placebo (n=131) until disease progression. Study results showed Lenvatinib-treated subjects lived a median of 18.3 months without their disease progressing (progression-free survival), compared to a median of 3.6 months for subjects who received placebo. Additionally, 65% of subjects treated with Lenvatinib saw a reduction in tumor size, compared to 2% of subjects who received a placebo.
Where should I keep Lenvatinib? Keep out of the reach of children. Store between 20 and 25 degrees C (68 and 77 degrees F). Throw away any unused medicine after the expiration date. NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.
1
AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com